METASTATIC LUNG NON-SMALL CELL CARCINOMA
Clinical trials for METASTATIC LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough lung cancer
Disease control OngoingThis early-phase trial tests whether adding bevacizumab to brigatinib can help people with ALK-positive non-small cell lung cancer whose disease has worsened on previous ALK-targeted therapy. The study enrolls just 5 patients and focuses on safety, side effects, and finding the b…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New hope for brain lining cancer: immunotherapy injected directly into spinal fluid
Disease control OngoingThis early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo shows promise for lung cancer brain metastases
Disease control OngoingThis phase II trial tested whether adding bevacizumab to osimertinib works better than osimertinib alone for patients with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. Only 5 patients were enrolled. The goal was to see if t…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two targeted drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goals are to find the safest dose and understand side effects.…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control OngoingThis early-phase trial is testing two oral drugs, Sapanisertib and Telaglenastat, in 22 people with advanced non-small cell lung cancer that has spread to the brain or other organs. The drugs work by blocking key enzymes that cancer cells need to grow. The main goal is to find th…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo targets tough lung cancer in early trial
Disease control OngoingThis early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable a…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental combo targets lung cancer brain metastases in early trial
Disease control OngoingThis early-phase trial is testing the safety and best dose of a drug called berzosertib when given together with whole brain radiation therapy. The study includes 15 people with lung cancer that has spread to the brain. The goal is to find out if this combination is safe enough t…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can adding radiation boost immunotherapy against tough cancers?
Disease control OngoingThis phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with or without radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 participants will receive the drugs alone or with hig…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug aims to shrink brain tumors by blocking cancer's growth signal
Disease control OngoingThis early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR that helps cancers grow, and is designed to reach…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cocktail aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis study tests whether adding two antibody drugs (trastuzumab and necitumumab) to the standard pill osimertinib can shrink tumors in people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to osimertinib alone. About 30 participants will r…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New cocktail of drugs shows promise for tough lung cancer
Disease control OngoingThis early-phase trial is testing a combination of four drugs—ensartinib, two chemotherapy drugs, and a targeted antibody—in 12 people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see how well the combination controls the disease.…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Vitamin a derivative combined with immunotherapy shows promise in early lung cancer trial
Disease control OngoingThis early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose an…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo aims to control advanced lung cancer
Disease control OngoingThis study tests a combination of two drugs—pembrolizumab (an immunotherapy) and trametinib (a targeted therapy)—in people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if the combination is safe and can shrink or control tumors. Partic…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill targets tough cancers: early trial underway
Disease control OngoingThis study tests an experimental oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma, a type of brain cancer. The drug is designed to block specific EGFR mutations that help these cancers grow. The trial has two p…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Cancer vaccine plus immunotherapy shows promise in Hard-to-Treat cancers
Disease control OngoingThis study combines the CIMAvax EGF vaccine with immunotherapy drugs (nivolumab or pembrolizumab) to treat advanced non-small cell lung cancer and squamous head and neck cancer. The vaccine aims to slow tumor growth, while the immunotherapy helps the immune system attack cancer c…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cord blood cells engineered to fight lung cancer enter human testing
Disease control OngoingThis early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer ce…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Smart radiation planning may ease lung cancer treatment side effects
Symptom relief OngoingThis study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC